bearish
SinoMab (中国抗体): Pipeline Concentrated on Autoimmune Therapy
656 Views19 Jul 2019 11:28
SinoMab, the first Hong Kong-headquartered biotech company coming to list on the SEHK, plans to raise USD100 to 200 million.
In this insight, we...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 6-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- SinoMab (中国抗体): Pipeline Concentrated on Autoimmune Therapy19 Jul 2019
- Okja: The Fight Between Netflix Vs. CJ CGV05 Jun 2017
- Netflix & Amazon Expand in Korea – Not a Coincidence20 Jan 2016
- Thoughts on Amazon –What Does Its Valuation Tells Us?01 Dec 2015
x